 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| PPCH CEO Discusses Strategy How to Get Novel Cancer Med to the Markets Fast |
|
 Hot Stock to Watch |
Company: Propanc Biopharma Inc. (OTCQB: PPCH)
|
Last:
Price: 1.35
Change (%): + 0.05 (3.57)
Volume: 24,224 |
 |
A New Audio Interview with James Nathanielsz, Propanc Biopharma Inc.'s Chief Executive Officer, is now at SmallCapVoice.com
AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) - Propanc Biopharma Inc. (OTCQB:PPCH) (“Propanc Biopharma” or “the Company”), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that a new audio interview with the Company, is now available. The interview can be heard at http://smallcapvoice.com/blog/5-19-17-smallcapvoice-interview-with-propanc-biopharma-inc-ppch.
James Nathanielsz, Propanc’s Chief Executive Officer, called in to SmallCapVoice.com, Inc. to go over Company’s business model, the markets they serve, how they got to where they are today and the goals for the Company in 2017. Recently, the Company announced that fresh new insights have emerged into how cancer stem cells (CSCs) are able to resist standard treatments, become more aggressive and spread rapidly. Published in Oncogene, by researchers from the Bellvitge Biomedical Research Institute south of Barcelona, Spain, the findings have significant implications for Propanc Biopharma’s lead product PRP, which reprograms CSCs so that they are no longer malignant and a threat to the patient. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.
In the interview, Mr. Nathanielsz states, “Right now, based on all the information we’ve been able to generate and the scientific data that supports our efforts, what we’re really focused on is two key aspects for the Company and they are quite simple: One, get this product to patients as soon as possible. Two, if it works, get it to as many patients as possible. We appreciate the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
